There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD), Histogenics (NASDAQ: HSGX) and Masimo Corp (NASDAQ: MASI) with bullish sentiments.
Clearside Biomedical (NASDAQ: CLSD)
In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares closed yesterday at $10.74.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.9% and a 53.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Clearside Biomedical is Strong Buy and the average price target is $27, representing a 151.4% upside.
In a report issued on June 7, JMP Securities also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Histogenics (NASDAQ: HSGX)
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Histogenics (NASDAQ: HSGX), with a price target of $5. The company’s shares closed yesterday at $2.83.
Zimmerman said:
“Underway HSGX hosted an analyst day, providing color on MD and patient experiences with NeoCart, as well as clarity around the strategy for the planned NeoCart launch. HSGX highlighted NeoCart as a platform technology that has multiple opportunities beyond knee cartilage longer- term. While there was not much mgmt. could say at the event specific to the Ph. 3 data itself (expected in 3Q18), as previewed (here) we expect a positive outcome. The hurdle to achieve statistical significance appears achievable based on Ph. 2 data (requiring a 15%-20% difference in the responder analysis between treatment and control). Our view was further supported by anecdotal feedback from MDs (in the Ph. 3 trial) and a patient who all had experience with NeoCart. $5 PT.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 34.2% and a 77.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.
Currently, the analyst consensus on Histogenics is Moderate Buy and the average price target is $4.25, representing a 50.2% upside.
In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $3.50 price target.
Masimo Corp (NASDAQ: MASI)
BTIG analyst Sean Lavin maintained a Buy rating on Masimo Corp (NASDAQ: MASI) on June 19 and set a price target of $120. The company’s shares closed yesterday at $101.19, close to its 52-week high of $102.32.
Lavin wrote:
“Raising PT to $120 from $100 Last week, we hosted investor meetings in with CFO Kammerman, vice president of Investor Relations. Mgmt discussed the company’s co- marketing agreement with Philips (PHG, Not Rated), product pricing, investments in R&D, and the potential to return cash to shareholders. It is our view that the bulk of benefits from the PHG partnership is yet to come, as integration took some time and securing hospital contracts usually takes 12-18 months. Since hospitals often sign multi-year contracts, this points to potentially improved growth in 2019 and beyond. We felt these were positive meetings and feel MASI’s new CFO is very committed to delivering on guidance. We increase our P/E valuation multiple and raise our PT to $120 (from $100) on increased confidence, the potential for more sales growth, and the fact that multiples in medtech continue to expand.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 17.2% and a 65.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
Masimo Corp has an analyst consensus of Moderate Buy, with a price target consensus of $107.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
